BioCentury
DATA GRAPHICS | Data Byte

The ɣδ T cell therapy pipeline

At least 11 companies are developing ɣδ T cell therapies for cancer, five of which have a candidate in the clinic

November 11, 2021 12:33 AM UTC

A small but growing group of companies aim to harness the unique properties of the γδ subset of T cells to create cell therapies with potential advantages for targeting solid tumors and off-the-shelf delivery.

The TCR of γδ cells is MHC independent, which may make the cells a good fit for allogeneic therapy because the TCR shouldn’t trigger graft-versus-host reactions. The TCR also targets cell stress markers, meaning it has not one but a set of targets that may increase tumor-selectivity and lead to the improved therapeutic index required for solid tumor treatment...